000			01968 a2200505 4500
005			20250516025657.0
264		0	_c20110527
008			201105s 0 0 eng d
022			_a1527-7755
024	7		_a10.1200/JCO.2010.32.1075 _2doi
040			_aNLM _beng _cNLM
100	1		_aCohn, David E
245	0	0	_aAt what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. _h[electronic resource]
260			_bJournal of clinical oncology : official journal of the American Society of Clinical Oncology _cApr 2011
300			_a1247-51 p. _bdigital
500			_aPublication Type: Journal Article; Webcast
650	0	4	_aAntibodies, Monoclonal _xadministration & dosage
650	0	4	_aAntibodies, Monoclonal, Humanized
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects
650	0	4	_aBevacizumab
650	0	4	_aCarboplatin _xadministration & dosage
650	0	4	_aChemotherapy, Adjuvant
650	0	4	_aComputer Simulation
650	0	4	_aCost-Benefit Analysis
650	0	4	_aDisease-Free Survival
650	0	4	_aDrug Costs
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aIntestinal Perforation _xeconomics
650	0	4	_aModels, Economic
650	0	4	_aNeoplasm Staging
650	0	4	_aOvarian Neoplasms _xdrug therapy
650	0	4	_aPaclitaxel _xadministration & dosage
650	0	4	_aRandomized Controlled Trials as Topic
650	0	4	_aSurvival Analysis
650	0	4	_aSurvival Rate
650	0	4	_aTime Factors
650	0	4	_aTreatment Outcome
700	1		_aKim, Kenneth H
700	1		_aResnick, Kimberly E
700	1		_aO'Malley, David M
700	1		_aStraughn, J Michael
773	0		_tJournal of clinical oncology : official journal of the American Society of Clinical Oncology _gvol. 29 _gno. 10 _gp. 1247-51
856	4	0	_uhttps://doi.org/10.1200/JCO.2010.32.1075 _zAvailable from publisher's website
999			_c20655845 _d20655845